<DOC>
	<DOCNO>NCT00215163</DOCNO>
	<brief_summary>Both pharmacotherapeutic psychosocial intervention domenstrated efficacy PTSD . However , although intervention helpful , many patient remain symptomatic despite initial treatment . In study , examine relative efficacy addition paroxetine-CR compare placebo patient remain symptomatic despite brief intensive course cognitive-behavioral therapy ( CBT ) .</brief_summary>
	<brief_title>Paroxetine-CR Treat Post-Traumatic Stress Disorder ( PTSD ) Symptomatic After Initial Exposure Therapy</brief_title>
	<detailed_description>This systematic control study examine use augmentation pharmaotherapy PTSD patient remain symptomatic despite CBT ( exposure therapy ) . The aim study include examination : ( 1 ) efficacy paroxetine-CR compare placebo addition ongoing exposure therapy patient fail respond brief , intensive CBT ; ( 2 ) tolerability paroxetine-CR compare placebo addition ongoing exposure therapy patient fail respond brief , intensive CBT ; ( 3 ) outcome patient 6 month follow-up randomized treatment . Patients initially intensive ( 8 session 4 week ) prolong exposure therapy . Patients remain symptomatic randomzied receive either flexibly-dosed paroxetine-CR ( 12.5 mg/d - 62.5 mg/d ) placebo conjunction additional 5 session prolong exposure 10 week .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Stress Disorders , Traumatic</mesh_term>
	<mesh_term>Stress Disorders , Post-Traumatic</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<criteria>Male female outpatient least 18 year age primary ( condition central patient 's current distress ) psychiatric diagnosis PTSD define DSMIV criterion Patients must remain symptomatic ( CGIS &gt; = 3 ) score least 6 SPRINT minimum 7 session prolong exposure ( deliver within 6 week ) eligible randomize treatment . Serious medical illness instability hospitalization may likely within next 3 month Pregnant lactate woman childbearing potential use medically accept form contraception Concurrent use psychotropic medication Lifetime diagnosis schizophrenia psychotic disorder , mental retardation , organic mental disorder , bipolar disorder ObsessiveCompulsive Disorder , eat disorder , alcohol/substance abuse disorder within last 6 month A current primary diagnosis major depression , dysthymia , social anxiety disorder , generalize anxiety disorder A history hypersensitivity poor response paroxetine use antidepressant , buspirone , betablockers within 2 week randomization Concurrent dynamic supportive psychotherapy start within 2 month prior onset study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>PTSD</keyword>
	<keyword>Anxiety</keyword>
	<keyword>CBT</keyword>
	<keyword>Exposure</keyword>
	<keyword>Paroxetine</keyword>
	<keyword>Paroxetine-CR</keyword>
</DOC>